These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 25165994)

  • 21. Risk factors for ocular infection with Chlamydia trachomatis in children 6 months following mass treatment in Tanzania.
    Cajas-Monson LC; Mkocha H; Muñoz B; Quinn TC; Gaydos CA; West SK
    PLoS Negl Trop Dis; 2011 Mar; 5(3):e978. PubMed ID: 21423645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors for ocular chlamydia after three mass azithromycin distributions.
    Ayele B; Gebre T; Moncada J; House JI; Stoller NE; Zhou Z; Porco TC; Gaynor BD; Emerson PM; Schachter J; Keenan JD
    PLoS Negl Trop Dis; 2011 Dec; 5(12):e1441. PubMed ID: 22180804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Profound and sustained reduction in Chlamydia trachomatis in The Gambia: a five-year longitudinal study of trachoma endemic communities.
    Burton MJ; Holland MJ; Makalo P; Aryee EA; Sillah A; Cohuet S; Natividad A; Alexander ND; Mabey DC; Bailey RL
    PLoS Negl Trop Dis; 2010 Oct; 4(10):. PubMed ID: 20957147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of Infection with Chlamydia trachomatis from Migrants to Communities Undergoing Mass Drug Administration for Trachoma Control.
    West SK; Munoz BE; Mkocha H; Gaydos C; Quinn T
    Ophthalmic Epidemiol; 2015; 22(3):170-5. PubMed ID: 26158574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Azithromycin in control of trachoma.
    Schachter J; West SK; Mabey D; Dawson CR; Bobo L; Bailey R; Vitale S; Quinn TC; Sheta A; Sallam S; Mkocha H; Mabey D; Faal H
    Lancet; 1999 Aug; 354(9179):630-5. PubMed ID: 10466664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is there evidence for resistance of ocular Chlamydia trachomatis to azithromycin after mass treatment for trachoma control?
    West SK; Moncada J; Munoz B; Mkocha H; Storey P; Hardick J; Gaydos CA; Quinn TC; Schachter J
    J Infect Dis; 2014 Jul; 210(1):65-71. PubMed ID: 24446528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment coverage of mass administration of azithromycin among children aged 1-11 months in 21 districts of Kebbi state, Nigeria.
    Wamyil-Mshelia T; Madaki S; Isiyaku S; Shu'aibu J; Olobio NP; Aliero AA; Abdulsalam M; Taiwo J; McDickoh VJ
    Int Health; 2023 Dec; 15(Supplement_2):ii12-ii18. PubMed ID: 38048379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased carriage of macrolide-resistant fecal E. coli following mass distribution of azithromycin for trachoma control.
    Seidman JC; Coles CL; Silbergeld EK; Levens J; Mkocha H; Johnson LB; Muñoz B; West SK
    Int J Epidemiol; 2014 Aug; 43(4):1105-13. PubMed ID: 24659584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control.
    Burr SE; Hart J; Edwards T; Harding-Esch EM; Holland MJ; Mabey DC; Sillah A; Bailey RL
    BMC Public Health; 2014 Nov; 14():1176. PubMed ID: 25407464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cohort and age effects of mass drug administration on prevalence of trachoma: a longitudinal study in rural Tanzania.
    Shekhawat N; Mkocha H; Munoz B; Gaydos C; Dize L; Quinn TC; West SK
    Invest Ophthalmol Vis Sci; 2014 Apr; 55(4):2307-14. PubMed ID: 24448262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma.
    West SK; Bailey R; Munoz B; Edwards T; Mkocha H; Gaydos C; Lietman T; Porco T; Mabey D; Quinn TC
    PLoS Negl Trop Dis; 2013; 7(8):e2415. PubMed ID: 24009792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Geospatial distribution and clustering of Chlamydia trachomatis in communities undergoing mass azithromycin treatment.
    Yohannan J; He B; Wang J; Greene G; Schein Y; Mkocha H; Munoz B; Quinn TC; Gaydos C; West SK
    Invest Ophthalmol Vis Sci; 2014 Jun; 55(7):4144-50. PubMed ID: 24906862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study.
    West SK; Munoz B; Mkocha H; Holland MJ; Aguirre A; Solomon AW; Foster A; Bailey RL; Mabey DC
    Lancet; 2005 Oct; 366(9493):1296-300. PubMed ID: 16214600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One round of azithromycin MDA adequate to interrupt transmission in districts with prevalence of trachomatous inflammation-follicular of 5.0-9.9%: Evidence from Malawi.
    Kalua K; Chisambi A; Chinyanya D; Masika M; Bakhtiari A; Willis R; Emerson PM; Solomon AW; Bailey RL
    PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006543. PubMed ID: 29897902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment.
    Coles CL; Mabula K; Seidman JC; Levens J; Mkocha H; Munoz B; Mfinanga SG; West S
    Clin Infect Dis; 2013 Jun; 56(11):1519-26. PubMed ID: 23487375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serology for trachoma surveillance after cessation of mass drug administration.
    Martin DL; Bid R; Sandi F; Goodhew EB; Massae PA; Lasway A; Philippin H; Makupa W; Molina S; Holland MJ; Mabey DC; Drakeley C; Lammie PJ; Solomon AW
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003555. PubMed ID: 25714363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between Community Drug Administration Strategy and Changes in Trachoma Prevalence, 2007 to 2013.
    Liu B; Cowling C; Hayen A; Watt G; Mak DB; Lambert S; Taylor H; Kaldor JM
    PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004810. PubMed ID: 27385309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma.
    Fraser-Hurt N; Bailey RL; Cousens S; Mabey D; Faal H; Mabey DC
    Bull World Health Organ; 2001; 79(7):632-40. PubMed ID: 11477966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mass drug administration with azithromycin for trachoma elimination and the population structure of Streptococcus pneumoniae in the nasopharynx.
    Gladstone RA; Bojang E; Hart J; Harding-Esch EM; Mabey D; Sillah A; Bailey RL; Burr SE; Roca A; Bentley SD; Holland MJ
    Clin Microbiol Infect; 2021 Jun; 27(6):864-870. PubMed ID: 32750538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coverage, social mobilization and challenges of mass Zithromax administration campaign in South and South East zones of Tigray, Northern Ethiopia: A cross sectional study.
    Mulugeta A; Gebregergs GB; Asfaw S; Yemane D; Mitiku M; Meresa B; Gigar G; Kidane A
    PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006288. PubMed ID: 29481558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.